Treatment with hAAT had no effect on TNFα levels in this model of CMT1A, as evidenced by a significant increase in plasma TNFα concentration observed on days 14 and 29 compared to the baseline concentration, which was not significantly different from that observed in the CMT1A + vehicle group (Supplementary Figure S1F). Here, PMP22 is linked to Charcot-Marie-Tooth disease type 1A.